PEAK6 Investments’s United Therapeutics UTHR Stock Holding History

PEAK6 Investments’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,000	Closed	-$221K	–	4616
2023 Q2	$221K	Sell	1,000 -4,600	-82%	-$1.02M	﹤0.01%	2811
2023 Q1	$1.25M	Buy	+5,600	New	+$1.38M	0.01%	1662
2022 Q3	–	Sell	-1,000	Closed	-$221K	–	5687
2022 Q2	$221K	Buy	+1,000	New	+$203K	﹤0.01%	2812
2020 Q3	–	Sell	-43,100	Closed	-$5.21M	–	4920
2020 Q2	$5.21M	Buy	43,100 +36,900	+595%	+$4.15M	0.02%	802
2020 Q1	$588K	Buy	+6,200	New	+$589K	﹤0.01%	1947
2019 Q4	–	Sell	-99,600	Closed	-$7.94M	–	4118
2019 Q3	$7.94M	Sell	99,600 -81,100	-45%	-$6.53M	0.05%	460
2019 Q2	$14.1M	Buy	180,700 +90,300	+100%	+$8.44M	0.09%	244
2019 Q1	$10.6M	Buy	+90,400	New	+$10.5M	0.06%	342

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

PEAK6 Investments's UTHR Position: Q3 2023 in Review

PEAK6 Investments sold out of United Therapeutics (UTHR) in Q3 2023, closing a stake of 3 shares — an estimated $651 sold.

PEAK6 Investments first reported a position in UTHR in Q1 2019 and held it in 11 quarters. The position peaked at $11.2M in Q2 2019. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

PEAK6 Investments reported no remaining United Therapeutics position as of Q3 2023 after selling out during the quarter.
PEAK6 Investments sold 3 United Therapeutics shares in Q3 2023, an estimated $651.
PEAK6 Investments first reported a position in United Therapeutics in Q1 2019 and held it in 11 quarters.
PEAK6 Investments's United Therapeutics position peaked at $11.2M in Q2 2019.
508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on PEAK6 Investments's 13F filing for Q3 2023, filed 13 Nov 2023.